Hims & Hers Health (NYSE:HIMS) Coverage Initiated at JPMorgan Chase & Co.

Analysts at JPMorgan Chase & Co. initiated coverage on shares of Hims & Hers Health (NYSE:HIMS) in a report released on Friday, MarketBeat reports. The firm set an “overweight” rating and a $35.00 price target on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 14.30% from the stock’s previous close.

Several other research firms also recently weighed in on HIMS. Evercore set a $24.00 price target on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Leerink Partners increased their price target on shares of Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research report on Monday, March 16th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Friday, March 27th. TD Cowen decreased their price target on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a research report on Friday, March 27th. Finally, Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Four investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $32.53.

Hims & Hers Health Stock Up 8.8%

HIMS opened at $30.62 on Friday. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $70.43. The company has a market capitalization of $6.98 billion, a PE ratio of 60.04, a PEG ratio of 2.67 and a beta of 2.32. The firm’s 50 day simple moving average is $20.98 and its two-hundred day simple moving average is $31.36.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. During the same period last year, the firm earned $0.11 earnings per share. The company’s quarterly revenue was up 28.4% on a year-over-year basis. As a group, equities analysts forecast that Hims & Hers Health will post 0.61 EPS for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 97,289 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the transaction, the chief operating officer owned 407,282 shares in the company, valued at $10,055,792.58. This trade represents a 19.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Soleil Boughton sold 9,463 shares of the stock in a transaction on Monday, April 20th. The shares were sold at an average price of $30.00, for a total transaction of $283,890.00. Following the transaction, the insider owned 299,368 shares of the company’s stock, valued at $8,981,040. This trade represents a 3.06% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 204,857 shares of company stock valued at $5,285,706. Insiders own 13.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors have recently bought and sold shares of the business. Farallon Capital Management LLC lifted its holdings in shares of Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after acquiring an additional 2,533,271 shares during the last quarter. Norges Bank bought a new stake in Hims & Hers Health during the 4th quarter valued at about $62,153,000. Invesco Ltd. lifted its holdings in Hims & Hers Health by 62.7% during the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after buying an additional 1,600,004 shares in the last quarter. Clear Street Group Inc. bought a new stake in Hims & Hers Health during the 3rd quarter valued at about $87,372,000. Finally, Marex Group plc lifted its holdings in Hims & Hers Health by 162.2% during the 4th quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock valued at $78,562,000 after buying an additional 1,496,707 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Expanded Lilly partnership — HIMS expanded its platform to let clinicians prescribe Eli Lilly GLP‑1 products (Zepbound, KwikPen, Foundayo) with fulfillment via LillyDirect, widening its weight‑management offering and creating a clearer prescription revenue path. Article Title
• Positive Sentiment: JPMorgan initiation — JPMorgan initiated coverage with an Overweight rating and $35 price target, framing the Novo Nordisk partnership and broader GLP‑1 access as a potential turning point; that institutional endorsement lifted sentiment. Article Title
• Positive Sentiment: Product expansion into women’s care — HIMS is scaling menopause/perimenopause offerings (including estrogen patches) and boosting peptide capabilities, which broadens recurring‑care revenue streams beyond legacy DTC categories. Article Title
• Neutral Sentiment: Regulatory tailwind but with open questions — The FDA scheduled a July compounding advisory committee meeting on certain peptides; the market views this as validating peptide opportunity but outcome/timing remain uncertain. Article Title
• Neutral Sentiment: Analyst/target moves — Bank of America raised its target to $32 (Neutral) and several other shops have adjusted coverage; upgrades add support but consensus remains mixed, so analyst activity amplifies swings rather than resolving execution risk. Article Title
• Negative Sentiment: Insider selling — CFO Oluyemi Okupe and other insiders sold shares under Rule 10b5‑1 plans (SEC filings), which can sap near‑term sentiment despite being pre‑arranged. Article Title
• Negative Sentiment: Competitive pressure — Amazon’s entry into GLP‑1/weight‑loss programs and other deep‑pocket competitors raise concerns about margin pressure and share erosion in a key growth category. Article Title

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.